Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Ketamine shows promise as a rapid-acting antidepressant, but its effectiveness varies.
• Predictors of ketamine response have been studied in adults, but not in adolescents with depression.
• Treatment-resistant depression in adolescents remains a significant clinical challenge.

Purpose of the Study:

• To identify demographic and clinical predictors of ketamine's antidepressant response in adolescents.
• To analyze secondary data from a randomized trial of ketamine for treatment-resistant depression in adolescents.
• To explore factors associated with depression symptom improvement following ketamine infusion.

Main Methods:

• Secondary data analysis of a randomized, single-dose, midazolam-controlled crossover trial.
• Examined 19 exploratory demographic and clinical variables.
• Assessed depression symptom improvement using the Montgomery-Åsberg Depression Rating Scale (MADRS) at 1 and 7 days postinfusion.

Main Results:

• Fewer prior antidepressant and augmentation medication trials predicted better ketamine response.
• Shorter duration of the current depressive episode was associated with greater symptom improvement.
• Treatment with selective serotonin reuptake inhibitors (SSRIs) and not serotonin-norepinephrine reuptake inhibitors (SNRIs) predicted better response.
• In the midazolam control group, less severe depressive symptoms (CDRS) and comorbid ADHD predicted increased response.

Conclusions:

• Preliminary findings suggest potential predictors for ketamine response in adolescents with depression.
• Fewer medication trials and shorter episode duration may indicate better treatment outcomes.
• Further research with larger sample sizes is necessary to establish clinical guidance for ketamine use in adolescent depression.